

1 **The clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using an-**
2 **tigen detecting diagnostics: a systematic review and meta-analysis**

3
4
5

6 Lukas E. Brümmer¹, Christian Erdmann², Hannah Tolle¹, Sean McGrath³, Ioana D. Oлару
7 ^{1,4}, Stephan Katzenschlager⁵, Seda Yerlikaya¹, Maurizio Grilli⁶, Nira R. Pollock⁷, Berra
8 Erkosar⁸, Aurelien Mace⁸, Stefano Ongarello⁸, Cheryl C. Johnson⁹, Jilian A. Sacks¹⁰, Clau-
9 dia M. Denkinge^{1,11*}

10
11

12 * Corresponding author (Claudia.Denkinge@uni-heidelberg.de)

13
14

15 1) Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Hei-
16 delberg University Hospital, Heidelberg, Germany

17 2) FH Muenster University of Applied Sciences, Muenster, Germany

18 3) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massa-
19 chusetts, United States of America

20 4) Department of Clinical Research, London School of Hygiene and Tropical Medicine, Lon-
21 don, United Kingdom

22 5) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

23 6) Library, University Medical Center Mannheim, Mannheim, Germany

24 7) Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts,
25 United States of America

26 8) FIND, Geneva, Switzerland

27 9) Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Swit-
28 zerland

29 10) Department of Epidemic and Pandemic Preparedness and Prevention, World Health Or-
30 ganization, Geneva, Switzerland

31 11) German Center for Infection Research (DZIF), partner site Heidelberg University Hospi-
32 tal, Heidelberg, Germany

33 **ABSTRACT**

34

35 **Introduction**

36 Self-testing for COVID-19 (C19ST) based on antigen detecting diagnostics could signifi-
37 cantly support controlling the SARS-CoV-2 pandemic. To inform the World Health Organization
38 in developing a C19ST guideline, we performed a systematic review and meta-analysis of the
39 available literature.

40

41 **Methods**

42 We electronically searched Medline and the Web of Science core collection, performed
43 secondary reference screening, and contacted experts for further relevant publications. Any
44 study published between December 1, 2020 and November 30, 2021 assessing the epidemi-
45 ological impact and clinical utility of C19ST was included. Study quality was evaluated using
46 the Newcastle Ottawa Scale (NOS). The review was registered on PROSPERO
47 (CRD42022299977).

48

49 **Results**

50 11 studies only from high-income countries with an overall low quality (median of 3/9 stars
51 on the NOS) were found. Pooled C19ST positivity was 0.2% (95% CI 0.1% to 0.4%; eight data
52 sets) in populations where otherwise no dedicated testing would have occurred. The impact of
53 self-testing on virus transmission was uncertain. Positive test results mainly resulted in people
54 having to isolate without further confirmation of results (eight data sets). When testing was
55 voluntary by study design, pooled testing uptake was 53.2% (95% CI 36.7% to 68.9%; five
56 data sets. Outside direct health impacts, C19ST reduced quarantine duration and absenteeism
57 from work, and made study participants feel safer. Study participants favored self-testing and
58 were confident that they performed testing and sampling correctly.

59

60 **Conclusions**

61 The present data suggests that C19ST could be a valuable tool in reducing the spread of
62 COVID-19, as it can achieve good uptake, may identify additional cases, and was generally
63 perceived as positive by study participants. However, data was very limited and heterogenous,
64 and further research especially in low- and middle-income countries is needed to assess the
65 clinical utility and epidemiological impact of C19ST in more detail.

66 **KEYWORDS**

67 COVID-19, diagnostics and tools, self-testing, control strategies, epidemiology, systematic
68 review, meta-analysis

69

70 **CONTRIBUTIONS TO THE LITERATURE**

71 - COVID-19 self-testing (C19ST) using antigen detection could conceivably support
72 pandemic control. A current PubMed search found no systematic evidence synthe-
73 sis of studies assessing the epidemiological impact and clinical utility of C19ST im-
74 plementation

75 - We systematically reviewed and meta-analyzed 11 studies including more than 1.1
76 million persons tested

77 - C19ST can achieve good uptake, may identify additional cases, and was general
78 perceived as positive by study participants, suggesting it to be a valuable tool in
79 reducing the spread of SARS-CoV-2

80 - Further data especially from low- and middle-income countries is needed to under-
81 stand the impact of C19ST in more detail

82 **BACKGROUND**

83 "We have a simple message for all countries: test, test, test." [1] With this statement at the
84 beginning of the COVID-19 pandemic, the World Health Organization's (WHO) director general
85 set the scene for what has developed into one of the main pillars for reducing the spread of
86 SARS-CoV-2 [2]. Detecting cases early in the course of the disease and when pre- or asymp-
87 tomatic has shown to be crucial for preventing further infections prior to the availability of vac-
88 cines [3-5]. Still, a large proportion of SARS-CoV-2 cases remain undiagnosed [6,7], or are
89 only diagnosed after most secondary transmissions have already occurred [8].

90 For detecting SARS-CoV-2, antigen-based rapid diagnostic tests (Ag-RDTs), using lat-
91 eral-flow assays, have become one of the main tools for testing. Compared to the gold-stand-
92 ard, real-time reverse transcriptase polymerase chain reaction (rRT-PCR), Ag-RDTs are less
93 accurate in detecting SARS-CoV-2 infection, but still detect over 90% of the cases with high
94 viral load in the early phase of disease [9]. In addition, they require minimal implementation
95 resources and are easy to use [10], allowing their widespread application. On a population
96 level, modelling studies show that the Ag-RDTs' disadvantage of lower accuracy is outweighed
97 by their potential to be implemented frequently and at large scale, thus conceivably detecting
98 cases earlier, which could result in reducing the spread of SARS-CoV-2 [11,12]. Moreover,
99 studies have shown Ag-RDTs to be similarly accurate when performed by lay users or medi-
100 cally-trained persons [13]. Consequently, Ag-RDTs have already been applied in multiple set-
101 tings as a tool for COVID-19 self-testing (C19ST) [14-17]. By increasing available testing ca-
102 pacity, C19ST using antigen-detection diagnostics could be an additional tool for pandemic
103 control if implemented at scale [18,19].

104 However, the clinical utility, i.e., the extent to which it improves health benefits, and the
105 epidemiological impact of implementing C19ST using Ag-RDTs has not yet been systemati-
106 cally evaluated [20]. Aiming to fill this gap in the literature and to assist the WHO in developing
107 a guideline for Ag-RDT based C19ST in March 2022 [19], we performed a systematic review
108 of the existing literature.

109 **METHODS**

110 A study protocol was developed (S1 Text), which follows standard guidelines for system-
111 atic reviews [21,22] and was reviewed by an independent methodologist contracted by the
112 WHO. We completed the PRISMA checklist (S1 PRISMA Checklist) and registered the review
113 on PROSPERO (registration number: CRD42022299977). This review was designed in close
114 cooperation with the WHO and the members of the guideline development group [19].

115

116 **Search strategy**

117 We searched for studies assessing the clinical utility and epidemiological impact of imple-
118 menting self-performed Ag-RDTs for SARS-CoV-2. A professional librarian (MG) electronically
119 searched MEDLINE (via PubMed) and Web of Science for any article published between De-
120 cember 1, 2020 and November 30, 2021. The main search terms were “Severe Acute Respir-
121 atory Syndrome Coronavirus 2”, “COVID-19”, “Betacoronavirus”, “Coronavirus”, “Self-testing”,
122 “home test”, and “Antigen” (details can be found in the Supplements, S2 Text). No geographic
123 or language restrictions were used.

124

125 **Study selection**

126 Two reviewers (LEB and HT) independently reviewed the titles and abstracts of all publi-
127 cations identified through the electronic search. Afterwards, three reviewers (LEB, HT and CE)
128 individually conducted a full-text review, to select the articles for inclusion in the systematic
129 review. As a final step, the three reviewers compared results with each other (for all steps
130 described using EndNote, version X9 [23]). Any disputes were resolved by discussion or by a
131 senior reviewer (CMD).

132 To be included in the review, a study had to implement C19ST using Ag-RDTs in a symp-
133 tomatic or asymptomatic population during the COVID-19 pandemic, compare this to a situa-
134 tion when no testing, professional use Ag-RDT testing or PCR-testing is performed, and meas-
135 ure one or more of the outcomes presented in Table 1, which were prioritized based on a
136 survey with the prospective members of the WHO Guideline Development Group (a detailed

137 explanation for each outcome is presented in the Supplement, S3 Text). We considered retro-
 138 spective or prospective cohort or nested cohort studies, case-control or cross-sectional stud-
 139 ies, before and after studies, as well as randomized studies. Where values and preferences
 140 for C19ST were reported by studies identified through the search, they were also descriptively
 141 summarized and reported (i.e., studies that assessed values and preferences only but without
 142 actually implementing C19ST were not considered). Studies with less than 100 study partici-
 143 pants were excluded. The review was limited to studies among human participants.

144

Outcomes	Sub-outcomes	Score	Rank
(1) Community level health impact	a) Proportion of infectious cases detected / positive test results	6	Important
	b) Impact on virus transmission	6	Important
	c) Impact on morbidity and/or mortality	6	Important
(2) Individual level health impact	a) Linkage for positive tests / actions after positive test result	7	Critical
	b) Social harm	7	Critical
	c) Testing uptake	6.5	Critical
	d) Time to diagnosis	6.5	Critical
	e) Testing frequency	6	Important
	f) Result reporting	6	Important
	g) Behavior change	5.5	Important
	h) Linkage for negatives / actions after negative test result	5	Important
(3) Broader societal effects		6	Important

145

146 **Table 1. Outcomes as ranked by the members of the WHO guideline development**
 147 **group**

148

149 In addition, references of the studies included into the review were manually searched by
 150 two reviewers (LEB and HT) to identify further studies for inclusion. Furthermore, selected
 151 experts in the field were contacted to identify additional articles not identified through the elec-
 152 tronic search. While the electronic search was limited to peer-reviewed data bases, we also
 153 considered any pre-print identified through secondary reference searching or contacting se-
 154 lected experts for inclusion.

155

156 **Data extraction and management**

157 Data extraction was performed by one reviewer (HT), using a standardized Google Sheets
158 form, and all extracted data was checked by a second reviewer (LEB). Any disagreements
159 about the data extracted were resolved through consensus or referral to a senior study team
160 member (CMD). Study authors were contacted if data was missing or there were questions on
161 the reporting of the outcomes. Several data sets were extracted from studies that assessed
162 multiple self-performed Ag-RDTs or presented results based on differing settings (e.g., school
163 vs. workplace). A full list of variables extracted can be found in the Supplements (S1 Table).

164

165 **Quality assessment**

166 To assess the quality of the included studies, the Newcastle-Ottawa Scale (NOS) was
167 employed [24]. Accounting for intra-study heterogeneity, if several data sets were extracted
168 from one study, these were assessed individually. Depending on the study's quality, stars are
169 assigned to each of the NOS's questions, leading to an overall zero-star-rating (worst) to nine-
170 star-rating (best) for each study. We prepared an interpretation guide specific for the research
171 question of this review for each of the questions on the NOS, which can be found in the Sup-
172 plements (S4 Text). The quality assessment was performed by two reviewers (LEB and HT)
173 independently. Any disputes were solved by discussion or by a third reviewer (CMD).

174

175 **Data analysis**

176 For quantitative outcomes, if four or more data sets were available, we prepared forest
177 plots, visually evaluated the heterogeneity between studies and conducted a meta-analysis
178 using random effects analysis. Specifically, we fit a random intercept logistic regression model
179 to meta-analyze the proportion of infectious cases detected and mean testing uptake [25]. For
180 outcomes where limited data was available, we performed a descriptive analysis.

181 We pre-defined the following categories to stratify outcomes and intended to meta-ana-
182 lyze based on these subgroup categories if reported by at least four papers: (1) frequency of
183 testing (one-off testing vs testing more than once; for testing more than once: testing at

184 random, i.e. without a fixed schedule, vs. testing as per a fixed schedule); (2) SARS-CoV-2
185 exposure (no known exposure, known exposure – single or multiple, unknown / not defined);
186 (3) test distributor (workplace, school/university, publicly available); (4) location of testing
187 (work, home, school/university); (5) cost per person to be tested (tests free of charge vs. pay-
188 ment required), (6) setting (rural or urban, gross domestic product (GDP) per capita [catego-
189 rized by World Trade Organization], literacy of the target population), (7) Ag-RDT used (com-
190 pany name, test and lot number, sample type), (8) assistance in sample collection or perform-
191 ing the test (no assistance vs. assisted in person by trained operator vs. assisted virtually by
192 trained operator vs. assisted in any other way), (9) symptomatic or asymptomatic study partic-
193 ipants (10) risk of COVID-19 related morbidity and mortality (as defined by study), (11) vac-
194 cination status (vaccinated vs. unvaccinated), (12) prior infection (convalescent vs. no known
195 infection), (13) age (persons \leq 18 years of age, persons 18 – 65 years of age, persons $>$ 65
196 years of age); (14) misuse, adverse events, social harms (specific to self-testing vs. issues that
197 occur in general for SARS-CoV-2 testing), (15) additional interventions (any other interventions
198 that were implemented to stop transmission besides C19ST for SARS-CoV-2, such as mask
199 wearing or travel restrictions).

200 The analyses were performed in R (version 4.1.3) with package “meta”. The R code and
201 the raw data are available at <https://github.com/stmcg/covid-testing-impact-ma>.

202

203 **Grading of evidence**


204 Following the GRADE approach [26], we prepared an interpretation guide specific for the
205 research question of this review for each of the GRADE aspects (S5 Text). Grading of evidence
206 was performed by one reviewer (LEB) and reviewed by a second (CCJ). Any disputes were
207 resolved by discussion or by a third reviewer (CMD). Using GRADE evidence profiles, a sum-
208 mary of the GRADE assessment for each outcome is presented in the results section, and a
209 detailed assessment in the Supplements (S6 Text).

210 **RESULTS**

211 **Study description**

212 The search yielded 2,722 records. After removing duplicates, 1,826 unique records re-
 213 mained, of which 1,642 were excluded based on title and abstract screening. The full text of
 214 182 articles was read, with seven being found to be eligible for inclusion in the review. Experts
 215 identified four additional reports, which were also included in the review. Overall, 11 studies
 216 were included [15-17,27-34], incorporating a total of 17 datasets (Fig 1). A list of the excluded
 217 studies can be found in the Supplement (S7 Text).

218



219

220 **Fig 1. PRISMA flow diagram.** Ag-RDT = antigen rapid diagnostic test

221

222 Most of the datasets were from the United Kingdom (8; 47.1% of all data sets)
 223 [15,16,28,29,33,34], and the others from Germany (4; 23.5% of all data sets) [17,27,32], Aus-
 224 tria (3; 17.6% of all data sets) [31], and the Netherlands (2; 11.8% of all data sets) [30]. In eight
 225 data sets (47.1% of all data sets) [15,16,28,29,33,34], the Innova SARS-CoV-2 Rapid Antigen
 226 Self-Test Kit (Innova Medical Group Inc., United States [CA]; henceforth called 'Innova') was

227 used. The STANDARD Q COVID-19 Ag Home Test (SD Biosensor, South Korea; distributed
228 in Europe by Roche, Germany; henceforth called 'Standard Q') [30,35] and the SARS-CoV-2
229 Antigen Rapid Test Kit (Lepu Medical Technology, China) [31] were used in three data sets
230 each (17.6% of all data sets). Of the remaining three data sets, one (5.9% of all data sets)
231 used the BD Veritor At-Home COVID-19 Test (Becton, Dickinson and Company, United States
232 [NJ]) [30], another the RIDA QUICK SARS-CoV-2 Antigen (R-Biopharm, German) [32] and for
233 the third the Ag-RDT used was unclear [27]. In eleven data sets (64.7% of all data sets), the
234 sample type was anterior nasal / mid-turbinate (AN/MT) [28-33,35], while the sample type used
235 in the remaining six data sets (35.3% of all data sets) was not reported [15,16,27,34].

236 In 14 datasets (77.8% of all datasets) [15-17,27-29,31-34], C19ST was implemented as
237 part of a routinely testing service, most often (4 datasets) [29,31,33,34] for testing twice weekly.
238 C19ST was mainly performed at home (10 data sets; 58.8%), but also in school (4; 23.5% of
239 all data sets) [27,31] or at work (1; 5.9% of all data sets) [34]. In two data sets (11.7% of all
240 data sets) from the same study, testing was performed at dedicated testing sites at the begin-
241 ning of the study and at home towards end of the study [16]. Study participation and self-testing
242 was free-of-charge in five data sets (27.8% of all data sets) [28,31], and there was no mention
243 of cost of tests in the other data sets.

244 From a total of 1,124,911 study participants, the majority (785,472; 69.8% of all partici-
245 pants) were school students and teachers, 325,655 (28.9%) were unselected study partici-
246 pants, i.e., from the general population, 13,050 (1.2%) were hospital and care home staff and
247 734 (0.1%) were university students and staff. For two data sets [15,27], the number of study
248 participants was unclear. 2,343 (0.3%) of all study participants were reported to be sympto-
249 matic, while 794,417 (70.6%) were asymptomatic and for the remaining 328,151 (29.2%) the
250 symptom status was unclear. Detailed characteristics of each data set included in the review
251 are presented in the Supplement (S2 Table, sheets 'study characteristics' and 'testing charac-
252 teristics').

253

254 **Quality assessment**

255 Overall, studies achieved a median of three (IQR 2.0 to 3.0) out of nine stars on the New-
256 castle Ottawa scale, indicating an overall low study quality (Supplement, S1 Fig). As outlined
257 above, studies were assessed in regards to the selection of their study population, the compa-
258 rability between study populations, and the assessment of the outcomes of interest for this
259 review. A detailed quality assessment for each study is presented in the Supplements (S1 Fig
260 and S3 Table, sheet 'study assessment').

261 In two out of 17 datasets (11.8%) [30,34], the study population for C19ST was likely rep-
262 resentative of the general population as it was sampled from the general population, enrolled
263 consecutively and with study participation rates above 90%. The remaining 15 (88.2%) da-
264 taset focused on sub-groups of the population (e.g., students) [15-17,27-29,31-33]. Where
265 studies included a comparator cohort, i.e., a cohort that did not perform C19ST (6 datasets,
266 35.3%) [27,28,30,33,34], this was always drawn from the same population as the exposed
267 cohort. The C19ST result was directly confirmed by study personnel (through observation of
268 the testing procedure) or review of an upload a picture of the test result in three datasets
269 (17.6%) [15,16]. For the remaining 14 (82.3%) datasets, test results were not confirmed (12
270 data sets) [15-17,28-32] or the process of documenting results was not further described (2
271 data sets) [27,34]. In 12 datasets (70.6%) [15-17,28,29,31,32], no other dedicated testing al-
272 ternative were offered to participants (i.e., counterfactual was no testing at all) with initiation of
273 the study. However, in five datasets (29.4%) [27,30,33,34], studies were conducted in settings
274 where persons were also tested by RT-PCR.

275 Two datasets (11.8%) excluded persons who had a positive SARS-CoV-2 test result
276 within the previous two months [27,29], enhancing comparability between study populations.
277 In all other datasets, persons were included irrespective of prior infection or their vaccination
278 status.

279 In three data sets (17.6%) [15,16], study personnel collected the data relevant to report
280 on the outcomes. In the remaining 14 datasets (82.4%) relevant data was only self-reported
281 by study participants (12 datasets) [15,17,28-33] or the procedure of data collection was un-
282 clear (2 data sets) [27,34]. In all but one dataset (94.1%) [33] the study period was clearly




Fig 2. Test positivity in settings where no testing was performed before

defined, suggesting that follow up was long enough for outcomes to occur. In three datasets (17.6%) [16,17,27], study participants were followed up adequately, i.e., for routine testing >80% of study participants followed the intended testing frequency across the whole study period. In four further data sets (23.5%) the loss to follow up was only minimal and therefore unlikely to introduce bias [15,31]. However, in the remaining 10 datasets (58.8%) [28-30,32-34] study results might have been biased due to loss of participants over the course of the study.


Community level health impact

Proportion of cases detected / test positivity: The number and proportion of positive C19ST results was reported in eight datasets. All were in settings where no dedicated testing was performed before. The meta-analyzed proportion of positive test results was 0.2% (95% CI 0.1% to 0.4%) [15,16,29,31,32,34]. Test positivity ranged from 0.7% in the general population of a large city in the UK (Liverpool) [15] to 0.0% in university-wide screening, also in the UK [16] (Fig 2). The data was overall limited and from only observational studies with low quality (median of 3 stars on the NOS; IQR 2.8 to 3.3), resulting in a very low certainty of evidence (Supplements S6 Text).

Impact on virus transmission: In one data set rRT-PCR was used to test care-home staff and inhabitants

311 weekly or monthly, respectively, or if symptomatic. In addition, in selected care-homes (hence-
312 forth called 'study care-homes') C19ST was offered to care-home staff twice weekly. Also,
313 visitors who tested negative through professional testing were allowed indoor visits. An in-
314 creased proportion of outbreaks, defined as at least two confirmed or clinically suspected
315 SARS-CoV-2 cases within two weeks, occurred in the study care homes (6 out of the 11 study
316 care homes, i.e., 54.5% [95% CI 23.4% to 83.3%]) compared to the standard care homes that
317 did not introduce self-testing for staff or allow indoor visits (26 out of 71 standard care homes,
318 i.e., 36.6% [95% CI 25.5% to 48.9%]). However, confidence intervals were widely overlapping
319 (Fig 3a) and it was not possible to distinguish whether differences were due to implementing
320 C19ST for care-home staff or allowing indoor visits. Of note, in one of the six study care-homes
321 experiencing an outbreak this was identified through C19ST, while in the other five the index
322 case was identified through routine or symptomatic rRT-PCR testing [34].

323



324

325 **Fig 3a and 3b. C19ST impact on virus transmission.** CI = confidence intervals.

326

327 In a separate study, adults who had been exposed to a confirmed case were offered daily
328 self-testing as an alternative to quarantine. Secondary attack rates were 6.3% (95% CI 3.4%
329 to 11.1%) when Ag-RDTs were used instead of quarantine and positive results were confirmed
330 by RT-PCR. In the comparator group, where quarantine was followed by a RT-PCR at day 7,
331 the secondary attack rate in contacts of study participants was similar 7.6% (95% CI 7.3% to

332 7.8%) [28] (Fig 3b). Overall, data was too limited to establish an association between self-
333 testing and virus transmission when implemented in a care-home or offered as an alternative
334 to quarantine after contact with cases (Supplement S6 Text).


335

336 **Individual level health impact**

337 *Linkage for positive tests:* Actions after a positive test result were reported in 11 datasets
338 across two different settings. In nine data sets, positive results in mostly asymptomatic people
339 required isolation (eight data sets) [16,17,29,31] or an invitation to seek confirmatory rRT-PCR
340 testing (one data set) [15]. Second, in two datasets, positive test results of contacts already in
341 quarantine required isolation [15,28]. In a total of five datasets [15,16,28,29], persons were
342 required to seek a confirmatory rRT-PCR test after a positive C19ST result. Where results of
343 the confirmatory rRT-PCR testing were reported, this is listed in the Supplements (S2 Table,
344 sheet 'testing characteristics'). Based on the limited data available, it is uncertain if self-testing
345 affected actions after a positive test result in a different way compared to professional testing
346 (Supplements S6 Text).

347 *Testing uptake:* In five datasets (10,336 individuals) testing was voluntary and the health
348 impact of self-testing in the community was examined [16,17,28,29]. Across these datasets,
349 testing uptake was estimated to be 53.2% (95% CI 36.7% to 68.9%), ranging from 75.7% in
350 hospital staff [29] to 25.8% in university students and staff [16] (Fig 4). However, all five da-
351 tasetes were from observational studies with a low quality (median of 3 stars on the NOS; IQR
352 3 to 3). Thus, evidence was judged to be of very low certainty (Supplements S6 Text).

353



354

355 **Fig 4. Testing uptake with self-test offer.**

356

357 *Time to diagnosis:* In eight data sets, positive C19ST results were used to inform the need
 358 for isolation. In three of these, self-testing was implemented for one-off testing in hospital staff
 359 and university students and staff [16,29], while in the other five it was implemented for regular
 360 screening in schools [17,31]. With self-testing providing results within 20-30 minutes [36,37],
 361 the time to inform the need for isolation can be assumed to fall in a similar range. However,
 362 self-testing was not reported to be considered a final SARS-CoV-2 diagnosis, e.g., for clinical
 363 decision making or official documentation, in any of the datasets. As the data come from only
 364 observational studies with low quality (median of 3 stars on the NOS; IQR 3 to 3.2), the evi-
 365 dence to support this was of very low certainty (Supplements S6 Text).

366 *Result reporting:* Reporting the test result following self-testing was required by study de-
 367 sign in four data sets [27,31]. Participants included in two datasets were contacted by tele-
 368 phone if they did not submit a test result and the proportion of results reported was 90.7% [30].
 369 The proportion of results reported was unclear in 10 data sets [15-17,28,29,32-34]. It was not
 370 possible to differentiate between the proportion of results reported according positive or nega-
 371 tive self-testing result. Again, overall, there was insufficient evidence to estimate the proportion
 372 of results reported in the general population or subgroups, but in the available data the propor-
 373 tion reported was high (> 90%) (Supplements S6 Text).

374 *Linkage for negatives:* Negative C19ST results were followed by the continuation of sta-
 375 tus-quo (e.g., continue with school operation, continue to work; 8 datasets) [16,17,31,33] or

376 the permission to leave quarantine for 24 hours (2 datasets) [15,28]. In eight of these datasets,
377 people had to retest within a given time interval (range 1 to 7 days) [15,17,28,31,33]. Based
378 on the limited data available, it is uncertain if self-testing affects actions after a negative test
379 result in a different way compared to professional testing (Supplements S6 Text).

380

381 **Broader societal effects**

382 C19ST was reported to be linked to reduced quarantine duration (2 datasets) [15,28] and,
383 consequently, decreased absenteeism from work (1 dataset) [15]. Self-testing also enabled
384 primary school students and staff to feel safer when having in-person lessons (2 data sets)
385 [17]. It is uncertain if self-testing affects absenteeism and provides other social benefits com-
386 pared to professional testing alone due to very low certainty evidence (Supplements S6 Text).
387 No reports of social harm or adverse events following C19ST were identified in the included
388 data sets.

389

390 **Further outcomes**

391 Additional data was not available for multiple outcomes, including impact on morbidity and
392 mortality. Details are presented in the Supplements (S8 Text).

393

394 **Values and preferences**

395 Three of the studies included in this review also reported on values and preferences to-
396 wards self-testing [28,30,34]. Furthermore, we found two studies, which did not assess any of
397 our review's outcomes [38,39], but reported the values and preferences of the study partici-
398 pants from two of the studies that were included in our review [16,28].

399 When asking study participants from the general population, who were offered daily self-
400 testing with AN/MT swabs as an alternative to quarantine after contact with a case [28], almost
401 70% had no concerns about performing daily self-testing [38]. In another study, persons also
402 from the general population were offered to self-test with an AN/MT swab after having been
403 tested by RT-PCR. Here, users were confident that they performed the test correctly and would

404 recommend self-testing to others [30]. Furthermore, interviewing university students and staff
405 when SARS-CoV-2 screening via self-testing was offered at their university [16], C19ST was
406 perceived to reduce the barriers to testing. Nonetheless, some staff and students were also
407 concerned that overoptimistic perceptions of the accuracy of self-testing could potentially lead
408 to change in risk behaviors [39]. Moreover, when implementing self-testing in the routines of a
409 care-home, a significant increase in workload and planning was reported by the care-home
410 staff [34].

411 **DISCUSSION**

412 Evaluating the clinical utility and epidemiological impact of Ag-RDT based C19ST in 11
413 studies, we found that C19ST received overall good uptake and may identify additional cases
414 compared to a situation where no dedicated testing is available. In addition, values and pref-
415 erences indicated that self-testing was generally considered acceptable and feasible, and peo-
416 ple perceived it as helpful and easy to perform. However, certainty of evidence was very low
417 for all of the outcomes assessed and the included studies showed a high risk of bias.

418 Assessing the community level health effect, C19ST achieved a pooled test positivity of
419 0.2% (95% CI 0.1% to 0.4%, when the alternative was no other dedicated testing in the given
420 setting to be available). Amongst other factors such as the sample type used [9], overall test
421 positivity depends especially on the test accuracy and the pre-test probability of being infected
422 [40]. While most studies deployed Ag-RDTs with similarly high accuracy estimates (Innova and
423 Standard Q; sensitivity 72.2% to 81.4% and specificity 99.1% to 99.3%), for the Ag-RDTs used
424 in the other studies varying accuracy is reported (sensitivity ranging from 39.2% to 77.6% and
425 specificity from 89.2% to 100%) [9]. In addition, the studies' populations and time during the
426 pandemic (within a surge or not) were very heterogenous, suggesting widely differing pre-test
427 probabilities [18]. Particularly, when pre-test probability is low (between waves), a substantial
428 proportion of positive results may be false positive, even though the Ag-RDT used most fre-
429 quently in the studies included shows a specificity close to 100% under real-life conditions [41].
430 For example, at 0.5% prevalence, for a test with 80% sensitivity and 99.5% specificity, only
431 about half of positive tests (44.6%) would be true positive. Thus, the overall proportion of
432 C19ST positives should be interpreted with caution. Nonetheless, given that no other routine
433 testing occurred in these mostly asymptomatic populations, it can be inferred that the cases
434 identified through a positive C19ST result might have not been detected without self-testing or
435 detected only later, when secondary transmission might have already occurred. Therefore,
436 C19ST could have identified cases that might have been missed otherwise, mitigating contin-
437 ued transmission and supporting outbreak control [42,43]. Countries and programs implement-
438 ing C19ST should focus on using quality-assured products such as those on the WHO

439 emergency list and may also want to consider how to best target C19ST toward those with
440 greater COVID-19 risks and vulnerabilities.

441 With regards to the individual level health effects, the uptake of C19ST was good overall
442 (53.2% [95% CI 36.7% to 68.9%]), but varied between study populations. The highest uptake
443 (75.7%) was found in health care workers [29]. This is not surprising, as health care workers
444 are likely experienced with COVID-19 testing and their frequent contact with vulnerable popu-
445 lations might foster their motivation to test [44]. In contrast, self-testing uptake was lowest
446 (25.8%) among university students and staff [16]. However, certain operational barriers might
447 have also limited uptake in this study. Students and staff were invited to test only via email and
448 had to download a smartphone app before they could take part in the testing. Self-testing up-
449 take might have been higher if staff and students had been approached in person. Nonethe-
450 less, university students and staff might feel less urgency to test for SARS-CoV-2 [45], reduc-
451 ing their motivation compared to health care workers. Further research is needed to investigate
452 where C19ST acceptance is highest, the determinants driving its uptake and possible inter-
453 ventions to support uptake.

454 In the available studies test results were only applied outside a patient / care-provider
455 interaction. Within the included studies, C19ST was mainly used to inform the need for isolat-
456 ing, potentially offering a much shorter turn-around time to decision than would have been
457 made via rRT-PCR (requiring usually 1 to 2 days until results are communicated). In contrast,
458 a negative self-testing result was mainly followed by the continuation of the status quo. Con-
459 sequently, self-testing enabled several positive effects outside of health, including people be-
460 ing allowed to leave quarantine for a fixed time interval or continue to work [15,28]. However,
461 there was no evidence to assess the impact of self-testing on virus transmission when used
462 as a tool to release from quarantine [15,28] or when used for mostly asymptomatic screening
463 [15,16,29,34,35]. Especially, when regular C19ST was implemented for care-home staff in par-
464 allel to professional testing of visitors with the opening of care-homes to indoor visits, it was
465 not possible to disentangle the impact of C19ST from that of visitor testing [34]. Thus, more

466 studies are needed to evaluate the effect of C19ST when replacing or adding to certain COVID-
467 19 restrictions.

468 Our study had several strengths. First, it followed rigorous methods, aligning to other WHO
469 commissioned reviews for self-testing, and being supported by an independent methodologist
470 contracted by WHO. In addition, we thoroughly assessed the studies included, utilizing the
471 Newcastle Ottawa Scale with an interpretation guide specific to the review question and fol-
472 lowing the GRADE approach to evaluate the certainty of evidence. Nonetheless, our study
473 might be limited by its underlying assumptions of C19ST being as accurate as Ag-RDTs when
474 performed by professional users. However, this assumption was based on best current scien-
475 tific knowledge [13] and is also reflected in the current WHO C19ST guideline [19]. In addition,
476 our study was limited by the small number of studies and data heterogeneity. For several out-
477 comes, performing a meta-analysis and drawing conclusions (e.g., for changes in mortality and
478 morbidity) was not possible. In addition, all studies included were only from high income coun-
479 tries, limiting the representativeness of our results outside of these areas. To foster the repre-
480 sentativeness of data, we consider it important for future studies to be done both in high- and
481 low-income countries and across different settings. Moreover, the potential impact of C19ST
482 on the implementation of new test and treat approaches will be important to monitor, as early
483 diagnosis is essential for effective treatment. Also, a better understanding of C19ST's resource
484 use enhance the comparison between implementing C19ST and professional testing. Finally,
485 studies should adhere to standard guidelines for conducting epidemiological or intervention
486 studies [46,47].

487

488 **CONCLUSION**

489 This review found that C19ST can achieve good uptake, and has the potential to identify
490 additional cases that might have gone undiagnosed if no dedicated testing were offered in
491 specific settings outside of health care facilities. C19ST was generally perceived as feasible
492 and easy to use by lay users, but utilizing C19ST to confirm a SARS-CoV-2 infection was not
493 reported. Data was limited for most outcomes and the overall risk of bias was high. The present

494 analysis together with further data presented to the guideline development group led WHO to
495 recommend the use of C19ST as an additional tool to control the COVID-19 pandemic [19].
496 However, further research, especially in low- and middle-income countries, is needed to thor-
497 oughly assess the epidemiological impact of C19ST.

498 **ACKNOWLEDGEMENTS**

499 We highly appreciate the methodological comments and edits from Prof. Elie Akl, Associ-
500 ate Dean for Clinical Research at the American University of Beirut, that strongly improved our
501 study protocol and manuscript. Furthermore, we are very grateful to Prof. Iain Buchan, Chair
502 in Public Health and Clinical Informatics, and Associate Pro Vice Chancellor for Innovation at
503 the University of Liverpool, Dr. David Hughes, Lecturer in Health Data Science at the University
504 of Liverpool, Dr. Paula Parvulescu, Consultant in Public Health Medicine at the Liverpool City
505 Council, Dr. John Tulloch, Tenure Track Fellow at the University of Liverpool, Assoc. Prof.
506 Volker Strenger, Research Lead in Infectiology at the Medical University of Graz, and Prof.
507 Peter Willeit, Professor of Clinical Epidemiology at the Medical University of Innsbruck, for
508 sharing further data from their studies.

509 **LIST OF ABBREVIATIONS**

510 Ag-RDT – Antigen-based rapid diagnostic tests

511 C19ST – COVID-19 self-testing

512 CI – Confidence Interval

513 GDP – Gross Domestic Product

514 NOS – Newcastle-Ottawa Scale

515 rRT-PCR – Real-time reverse transcriptase polymerase chain reaction

516 WHO – World Health Organisation

517 **DECLARATIONS**

518 **Ethics approval and consent to participate**

519 Not applicable.

520 **Consent for publication**

521 Not applicable.

522 **Availability of data and materials**

523 Data extracted from included studies and used for all analysis is publicly available under
524 <https://github.com/stmcg/covid-testing-impact-ma>.

525 **Competing interests**

526 The authors declare that they have no competing interests.

527 **Funding**

528 The study was supported by the Ministry of Science, Research and Arts of the State of Baden-
529 Wuerttemberg, Germany (no grant number; <https://mwk.badenwuerttemberg.de/de/startseite/>)
530 and internal funds from the Heidelberg University Hospital (no grant number; [https://www.hei-
531 delberg-universityhospital.com/de/](https://www.heidelberg-universityhospital.com/de/)) to CMD. Further, this project was funded by United King-
532 dom (UK) aid from the British people (grant number: 300341-102; Foreign, Commonwealth &
533 Development Office (FCMO), former UK Department of International Development (DFID);
534 www.gov.uk/fcdo), and supported by a grant from the World Health Organization (WHO; no
535 grant number; <https://www.who.int>) and a grant from Unitaid (grant number: 2019-32-FIND
536 MDR; <https://unitaid.org>) to the Foundation of New Diagnostics (FIND; SO, AM, BE). This study
537 was also funded by the National Science Foundation GRFP (grant number DGE1745303) to
538 SM. The funders had no role in study design, data collection and analysis, decision to publish,
539 or preparation of the manuscript. Finally, WHO used internal funds and funding provided by
540 Unitaid (under the WHO HIV and Co-Infections/Co-Morbidities Enabler Grant [HIV&COIMS],
541 no grant number; <https://unitaid.org>), to develop the C19ST guidelines.

542 **Authors' contributions**

543 LEB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project
544 administration, Resources, Supervision, Validation, Visualization, Writing – original draft,
545 Writing – review & editing
546 CE: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Valida-
547 tion, Writing – review & editing
548 HT: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing –
549 review & editing
550 SM: Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review

551 & editing
552 IDO: Writing – review & editing
553 SK: Writing – review & editing
554 SY: Visualization, Writing – review & editing
555 MG: Software, Writing – review & editing
556 NRP: Writing – review & editing
557 BE: Writing – review & editing
558 AM: Writing – review & editing
559 SO: Writing – review & editing
560 JAS: Formal analysis, Investigation, Methodology, Project administration, Writing – original
561 draft, Writing – review & editing
562 CJ: Formal analysis, Investigation, Methodology, Project administration, Writing – original
563 draft, Writing – review & editing
564 CD: Conceptualization, Investigation, Methodology, Project administration, Resources, Su-
565 pervision, Validation, Visualization, Writing – original draft, Writing – review & editing
566 All authors read and approved the final manuscript.

567 REFERENCES

- 568 1. World Health Organization. WHO Director-General's opening remarks at the media briefing
569 on COVID-19 - 16 March 2020. 2020.
- 570 2. World Health Organization. COVID-19 strategic preparedness and response plan. 2021.
- 571 3. Casey-Bryars M, Griffin J, McAloon C, Byrne A, Madden J, Mc Evoy D, et al. Presymptomatic
572 transmission of SARS-CoV-2 infection: a secondary analysis using published data. *BMJ Open*, 2021;
573 11(6):e041240. DOI:10.1136/bmjopen-2020-041240.
- 574 4. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. Viral dynamics of acute SARS-
575 CoV-2 infection and applications to diagnostic and public health strategies. *PLoS Biol*, 2021;
576 19(7):e3001333. DOI:10.1371/journal.pbio.3001333.
- 577 5. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-
578 2 - Singapore, January 23-March 16, 2020. *MMWR Morb Mortal Wkly Rep*, 2020; 69(14):411-415.
579 DOI:10.15585/mmwr.mm6914e1.
- 580 6. Irons NJ, Raftery AE. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests,
581 and random surveys. *Proc Natl Acad Sci U S A*, 2021; 118(31). DOI:10.1073/pnas.2103272118.
- 582 7. Reese H, Iuliano AD, Patel NN, Garg S, Kim L, Silk BJ, et al. Estimated Incidence of Coronavirus
583 Disease 2019 (COVID-19) Illness and Hospitalization-United States, February-September 2020. *Clin*
584 *Infect Dis*, 2021; 72(12):e1010-e1017. DOI:10.1093/cid/ciaa1780.
- 585 8. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics,
586 and controllability of SARS-CoV-2. *Science*, 2021; 371(6526). DOI:10.1126/science.abe2424.
- 587 9. Brümmer LE, Katzenschlager S, McGrath S, Schmitz S, Gaeddert M, Erdmann C, et al.
588 Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic
589 review and meta-analysis with meta regression analyzing influencing factors. *PLoS Med*, 2022;
590 19(5):e1004011. DOI:10.1371/journal.pmed.1004011.
- 591 10. Kruger LJ, Tanuri A, Lindner AK, Gaeddert M, Koppel L, Tobian F, et al. Accuracy and ease-of-
592 use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation.
593 *EBioMedicine*, 2022; 75:103774. DOI:10.1016/j.ebiom.2021.103774.
- 594 11. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit
595 the Safe Reopening of College Campuses in the United States. *JAMA Netw Open*, 2020;
596 3(7):e2016818. DOI:10.1001/jamanetworkopen.2020.16818.
- 597 12. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is
598 secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*, 2021; 7(1).
599 DOI:10.1126/sciadv.abd5393.
- 600 13. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head
601 comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus
602 professional-collected nasopharyngeal swab. *Eur Respir J*, 2021; 57(4).
603 DOI:10.1183/13993003.03961-2020.
- 604 14. Rosella LC, Agrawal A, Gans J, Goldfarb A, Sennik S, Stein J. Large-scale implementation of
605 rapid antigen testing system for COVID-19 in workplaces. *Sci Adv*, 2022; 8(8):eabm3608.
606 DOI:10.1126/sciadv.abm3608.
- 607 15. University of Liverpool Institute of Population Health. Covid-SMART Asymptomatic Testing
608 Pilot in Liverpool City Region: Quantitative Evaluation; 2021. Available from:
609 [https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool_City_Region_Covid_SMART_Evalu](https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool_City_Region_Covid_SMART_Evaluation.pdf)
610 [ation.pdf](https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool_City_Region_Covid_SMART_Evaluation.pdf); accessed Nov 30, 2021.
- 611 16. Hirst JA, Logan M, Fanshawe TR, Mwandigha L, Wanat M, Vicary C, et al. Feasibility and
612 Acceptability of Community Coronavirus Disease 2019 Testing Strategies (FACTS) in a University
613 Setting. *Open Forum Infect Dis*, 2021; 8(12):ofab495. DOI:10.1093/ofid/ofab495.
- 614 17. Wachinger J, Schirmer M, Tauber N, McMahan SA, Denking CM. Experiences with opt-in,
615 at-home screening for SARS-CoV-2 at a primary school in Germany: an implementation study. *BMJ*
616 *Paediatr Open*, 2021; 5(1):e001262. DOI:10.1136/bmjpo-2021-001262.
- 617 18. World Health Organization. Interim guidance: Antigen-detection in the diagnosis of SARS-
618 CoV-2 infection. 2021.

- 619 19. World Health Organization. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for
620 COVID-19 self-testing. 2022.
- 621 20. Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility
622 of diagnostic tests. *Clin Chem*, 2012; 58(12):1636-43. DOI:10.1373/clinchem.2012.182576.
- 623 21. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working
624 G. Systematic reviews of diagnostic test accuracy. *Annals of Internal Medicine*, 2008; 149(12):889-97.
625 DOI:10.7326/0003-4819-149-12-200812160-00008.
- 626 22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic
627 reviews and meta-analyses: the PRISMA statement. *Annals of Internal Medicine*, 2009; 151(4):264-9,
628 W64. DOI:10.7326/0003-4819-151-4-200908180-00135.
- 629 23. The EndNote Team. EndNote. EndNote X9 ed. Philadelphia, PA: Clarivate; 2013.
- 630 24. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
631 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013.
- 632 25. Lin L, Chu H. Meta-analysis of proportions using generalized linear mixed models.
633 *Epidemiology (Cambridge, Mass)*, 2020; 31(5):713.
- 634 26. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane Handbook for*
635 *Systematic Reviews of Interventions* version 6.2 (updated February 2021). 2021.
- 636 27. Kheiroddin P, Schoberl P, Althammer M, Cibali E, Wurfel T, Wein H, et al. Results of WICOVIR
637 Gargle Pool PCR Testing in German Schools Based on the First 100,000 Tests. *Front Pediatr*, 2021;
638 9:721518. DOI:10.3389/fped.2021.721518.
- 639 28. Love N, Ready D, Turner C, Yardley L, Rubin J, Hopkins S, et al. The acceptability of testing
640 contacts of confirmed COVID-19 cases using serial, self-administered lateral flow devices as an
641 alternative to self-isolation medRxiv [Preprint]; published March 26, 2021.
642 DOI:10.1101/2021.03.23.21254168.
- 643 29. Lamb G, Heskin J, Randell P, Mughal N, Moore LS, Jones R, et al. Real-world evaluation of
644 COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a
645 prospective cohort analysis. *J Infect*, 2021; 83(4):452-457. DOI:10.1016/j.jinf.2021.07.038.
- 646 30. Stohr JJM, Zwart VF, Goderski G, Meijer A, Nagel-Imming CRS, Kluytmans-van den Bergh
647 MFQ, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests for people
648 with suspected COVID-19 in the community. *Clin Microbiol Infect*, 2021.
649 DOI:10.1016/j.cmi.2021.07.039.
- 650 31. Willeit P, Bernar B, Zurl C, Al-Rawi M, Berghold A, Bernhard D, et al. Sensitivity and specificity
651 of the antigen-based anterior nasal self-testing programme for detecting SARS-CoV-2 infection in
652 schools, Austria, March 2021. *Eurosurveillance*, 2021; 26(34). DOI:10.2807/1560-
653 7917.Es.2021.26.34.2100797.
- 654 32. Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. High-Frequency Self-Testing
655 by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test. *Dtsch Arztebl Int*, 2021; 118(14):252-
656 253. DOI:10.3238/arztebl.m2021.0187.
- 657 33. Downs LO, Eyre DW, O'Donnell D, Jeffery K. Home-based SARS-CoV-2 lateral flow antigen
658 testing in hospital workers. *J Infect*, 2021; 82(2):282-327. DOI:10.1016/j.jinf.2021.01.008.
- 659 34. Tulloch JSP, Micocci M, Buckle P, Lawrenson K, Kierkegaard P, McLister A, et al. Enhanced
660 lateral flow testing strategies in care homes are associated with poor adherence and were
661 insufficient to prevent COVID-19 outbreaks: results from a mixed methods implementation study.
662 *Age Ageing*, 2021; 50(6):1868-1875. DOI:10.1093/ageing/afab162.
- 663 35. Wachinger J, Schirmer M, Täuber N, McMahan SA, Denking CM. Experiences with opt-in,
664 at-home screening for SARS-CoV-2 at a primary school in Germany: an implementation study. *BMJ*
665 *Paediatr Open*, 2021; 5(1):e001262. DOI:10.1136/bmjpo-2021-001262.
- 666 36. Korea) SBS. COVID-19 Ag Home Test; 2022. Available from:
667 https://www.sdbiosensor.com/product/product_view?product_no=295; accessed May 20, 2022.
- 668 37. Innova Medical Group (United States C. How Antigen Testing Works; 2022. Available from:
669 <https://innovamedgroup.com/how-antigen-testing-works/>; accessed May 20, 2022.

- 670 38. Martin AF, Denford S, Love N, Ready D, Oliver I, Amlôt R, et al. Engagement with daily testing
671 instead of self-isolating in contacts of confirmed cases of SARS-CoV-2. *BMC Public Health*, 2021;
672 21(1):1067. DOI:10.1186/s12889-021-11135-7.
- 673 39. Wanat M, Logan M, Hirst JA, Vicary C, Lee JJ, Perera R, et al. Perceptions on undertaking
674 regular asymptomatic self-testing for COVID-19 using lateral flow tests: a qualitative study of
675 university students and staff. *BMJ Open*, 2021; 11(9):e053850. DOI:10.1136/bmjopen-2021-053850.
- 676 40. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *Bmj*, 2020; 369:m1808.
677 DOI:10.1136/bmj.m1808.
- 678 41. Garcia-Finana M, Hughes DM, Cheyne CP, Burnside G, Stockbridge M, Fowler TA, et al.
679 Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic
680 testing pilot: population based cohort study. *Bmj*, 2021; 374:n1637. DOI:10.1136/bmj.n1637.
- 681 42. Leng T, Hill EM, Holmes A, Southall E, Thompson RN, Tildesley MJ, et al. Quantifying pupil-to-
682 pupil SARS-CoV-2 transmission and the impact of lateral flow testing in English secondary schools.
683 *Nat Commun*, 2022; 13(1):1106. DOI:10.1038/s41467-022-28731-9.
- 684 43. Zhang X, Barr B, Green M, Hughes D, Ashton M, Charalampopoulos D, et al. The impact of
685 community asymptomatic rapid antigen testing on COVID-19 hospital admissions: a synthetic control
686 study. *medRxiv [Preprint]*; published April 21, 2022.
- 687 44. Dalili MN, Long J, Wadley E, Sloan J, Cross A, Thomas KH, et al. Who is accessing community
688 lateral flow device testing and why? Characteristics and motivations of individuals participating in
689 COVID-19 community testing in two English local authority areas. *BMC Public Health*, 2022; 22:588.
- 690 45. Barry G, McCarney C, Farrelly M, Breathnach R, Mooney C, More SJ. Rapid antigen testing for
691 SARS-CoV-2 infection in a university setting in Ireland: Learning from a 6-week pilot study. *Public
692 Health Pract (Oxf)*, 2022:100255. DOI:10.1016/j.puhip.2022.100255.
- 693 46. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010
694 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin
695 Epidemiol*, 2010; 63(8):e1-37. DOI:10.1016/j.jclinepi.2010.03.004.
- 696 47. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
697 Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement:
698 guidelines for reporting observational studies. *Bull World Health Organ*, 2007; 85(11):867-72.
699 DOI:10.2471/blt.07.045120.

700